NRXP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases...

Stats
Today's Volume	762 514
Average Volume	194 516
Market Cap	28.90M
EPS	US089482100 ( 2024-03-28 )
Next earnings date	( US089482100 ) 2024-05-14
Last Dividend	US089482100 ( N/A )
Next Dividend	US089482100 ( N/A )
P/E	-0.750
ATR14	US089482100.0130 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Rehnquist Janet	Buy	0
2023-09-13	Narido Richard Clavano	Buy	0
2023-08-30	Gorovitz Aaron	Buy	35 000	Common Stock, par value $0.001 per share
2023-08-30	Hurvitz Chaim	Buy	70 000	Common Stock, par value $0.001 per share
2023-08-23	Javitt Jonathan C	Buy	100 000	Common Stock

INSIDER POWER
1.66
Last 86 transactions
Buy: 35 919 718 \| Sell: 5 833 033

Volume Correlation

Long: -0.31 (neutral)

Short: -0.54 (weak negative)

Signal:(36.112) Neutral

NRx Pharmaceuticals, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NRx Pharmaceuticals, Inc. Correlation - Currency/Commodity

-0.12
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.02
( neutral )

-0.31
( neutral )

0.02
( neutral )

NRx Pharmaceuticals, Inc. Financials

Annual	2023
Revenue:	US089482100
Gross Profit:	US08948210-5 000.00 (0.00 %)
EPS:	US08948210-3.98

Q4	2023
Revenue:	US089482100
Gross Profit:	US08948210-1 000.00 (0.00 %)
EPS:	US08948210-0.0516

Q3	2023
Revenue:	US089482100
Gross Profit:	US08948210-2 000.00 (0.00 %)
EPS:	US08948210-0.0740

Q2	2023
Revenue:	US089482100
Gross Profit:	US08948210-1 000.00 (0.00 %)
EPS:	US08948210-0.120

Financial Reports:

No articles found.

NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.